Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses microRNA product platform to develop chemically modified, single-stranded oligonucleotides which it calls anti-miRs. It uses these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state. In August 2012, the Company formed a strategic alliance with AstraZeneca to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology.